Cagrilintide + Retatrutide Quick Start
The cagrilintide + retatrutide stack combines two investigational weight-loss peptides. Retatrutide is Eli Lilly's triple agonist - one weekly injection that hits three receptors at once (GLP-1, GIP, glucagon). Cagrilintide is a long-acting amylin peptide from Novo Nordisk that mimics the fullness hormone your body makes after meals. Together they target four receptor pathways.
The community uses a few names for this combo: reta/cag, reta-cag blend, the LEAN blend, the 4-receptor stack, or supplier brand names like ma-3rt / cag and fg3-r / cag. All mean the same two-compound pair. This page covers what the stack does, how researchers dose it (pre-blend or separate vials), the reconstitution math for common blend ratios, side effects, and how it compares to CagriSema.
Format options
Pre-blended vials (most common: 12.5 mg reta + 2.5 mg cag) or two separate vials.
Schedule
Once weekly for both compounds. Same day, different injection sites.
Titration
Start retatrutide alone for 4-8 weeks, then add cagrilintide. Co-escalate slowly.
Reconstitution
Both compounds use U-100 insulin syringes. BAC water added slowly down the vial wall.
Research status
Both investigational. CagriSema (closest analog) has Phase 3 data.
Need broader context on combining peptides? See PepPal's stacking safety guide. For supplier and quality-control sourcing, see the PepPal supplier directory.
Disclaimer
This page is an educational research reference. It is not medical advice. No clinical trial has tested cagrilintide + retatrutide together. The dosing structure below is community-derived from each compound's own research plus the CagriSema (cagrilintide + semaglutide) Phase 3 data. Both compounds are investigational.
What Is the Cagrilintide + Retatrutide Stack?
The cagrilintide + retatrutide stack is a two-compound research protocol that pairs two of the most powerful weight-loss peptides in late-stage development. The plain-English version: retatrutide does the heavy lifting on appetite, blood sugar, and energy use. Cagrilintide adds a separate fullness signal that retatrutide does not hit on its own.
The idea behind this stack comes from Novo Nordisk's CagriSema program. CagriSema combined cagrilintide with semaglutide (a single-receptor GLP-1 drug). In the Phase 3 REDEFINE-1 trial, adding cagrilintide to semaglutide pushed average weight loss from 14.9% to 20.4%. The reta + cag stack swaps semaglutide for retatrutide - which already hits three receptors - aiming to layer amylin satiety on top of broader metabolic effects.
What Each Compound Does
Retatrutide (LY3437943) is a triple agonist: GLP-1 (cuts appetite, slows the stomach), GIP (improves insulin signaling), and glucagon (raises energy use and fat burning). In Phase 3 TRIUMPH-4, retatrutide at 12 mg produced 28.7% body weight loss at 68 weeks vs 2.1% for placebo.
Cagrilintide is a long-acting amylin analog. Amylin is a hormone released by your pancreas after meals. It works in the hindbrain (a different part of the brain than GLP-1) to tell you that you have had enough food. Cagrilintide alone produced about 11.8% weight loss at 68 weeks in monotherapy and roughly 20.4% combined with semaglutide in REDEFINE-1.
Why People Pair Them
Retatrutide is powerful, but it does not activate amylin receptors. Cagrilintide fills that gap. The combined logic is:
- Two separate fullness channels. GLP-1 (reta) tells your gut to slow down. Amylin (cag) tells your hindbrain you are full. Different brain regions, different pathways.
- Stacked digestion slowdown. Both compounds slow gastric emptying. Food stays in the stomach longer, which extends fullness after meals.
- Four receptor pathways covered. GLP-1 (appetite) + GIP (insulin) + glucagon (energy burn) + amylin (fullness). No other current peptide stack covers this many pathways.
- CagriSema rationale extended. REDEFINE-1 showed that adding amylin to a GLP-1 backbone improves results. This stack tests the same logic with a triple-agonist backbone.
Evidence boundary
No clinical trial has tested cagrilintide and retatrutide together. The pairing logic above is mechanistic and based on CagriSema results. The combined stack's evidence is theoretical.
Why Researchers Combine Cagrilintide and Retatrutide
Adding a second peptide to retatrutide only makes sense if it covers something retatrutide misses. Here is how each piece fits together.
Foundation - What Retatrutide Already Provides
Retatrutide is the most potent single-agent weight-loss peptide in late-stage trials. TRIUMPH-4 reported 28.7% mean weight loss at 68 weeks. It works through three receptor pathways at once: GLP-1 reduces appetite and slows digestion, GIP supports insulin sensitivity, and glucagon raises energy expenditure and fat oxidation.
The Missing Pathway - Amylin Satiety
Retatrutide hits three receptors, but not amylin. Amylin signals in the hindbrain (a separate part of the brain from where GLP-1 acts). The simplest way to picture it: GLP-1 tells your gut to slow down, while amylin tells your brain you are full - through a different channel. Stacking amylin on top of triple agonism is meant to amplify fullness through routes that do not overlap.
Stacked Digestion Slowdown
Both compounds slow gastric emptying through different mechanisms. Combining them can stretch fullness even longer after meals - but it also stacks the risk of nausea, vomiting, constipation, and difficulty stepping doses up. This is the single biggest practical concern with the stack.
Glucagon + Amylin - Overlapping but Different
Retatrutide hits the glucagon receptor directly, which pushes the body to burn more energy. Cagrilintide acts on calcitonin-related receptors that can influence some glucagon-adjacent signaling, but through a different mechanism. How these two effects interact when combined has not been studied, so the net effect on blood sugar is unknown.
Reminder
The pathways above describe compound-level research and mechanism. No published human trial has measured outcomes for cagrilintide + retatrutide as a stack. CagriSema is the closest evidence anchor, and it uses semaglutide, not retatrutide.
Cagrilintide + Retatrutide Dosing Protocol & Schedule
Evidence-level notice
No clinical trial has tested cagrilintide + retatrutide together. Combined protocols are community-derived from each compound's Phase 2/3 data plus CagriSema rationale. Treat this as high-speculation with conservative titration.
There are two common formats: a pre-blended vial (most often 12.5 mg retatrutide + 2.5 mg cagrilintide in one vial), or two separate vials dosed together. Pre-blends are simpler to handle but lock the ratio between the two compounds. Separate vials are more work but let you titrate each compound on its own schedule.
Cagrilintide + Retatrutide Dosing Guide
Choose the format you are using to see the matching schedule.
Simpler workflow at a fixed 5:1 ratio (commonly 12.5 mg retatrutide + 2.5 mg cagrilintide).
Most pre-blends sold as reta/cag, ma-3rt/cag, or fg3-r/cag use a 5:1 ratio. The most common version is 12.5 mg retatrutide + 2.5 mg cagrilintide in one 15 mg vial. Some suppliers also sell 10 mg + 2.5 mg or 8 mg + 2 mg blends. Pre-blends are easier to draw and inject, but you cannot raise one compound without raising the other.
Blend ratio
5 : 1 (reta : cag)
Retatrutide dominant
15 mg total per vial: 12.5 mg retatrutide and 2.5 mg cagrilintide. Reconstituted with 2.5 mL bacteriostatic water for a 6.0 mg/mL total-blend concentration.
Reconstitute
2.5 mL BAC water
Concentration
5.0 mg/mL reta + 1.0 mg/mL cag
Weekly draw range
0.40-2.40 mL (40-240 units)
Typical cycle
24-week ramp + maintenance
Dose selector
Component Delivery (12.5/2.5 mg Blend)
| Retatrutide | 2.0 mg |
|---|---|
| Cagrilintide | 0.4 mg |
* Volumes above 100 units exceed a standard 1 mL insulin syringe - split into two injections or use a larger syringe. The fixed 5:1 ratio means you cannot start low on one compound while ramping the other - if you raise retatrutide, cagrilintide goes up proportionally. For staggered titration, separate vials are better.
Pre-Blend Weekly Schedule Example
Pre-blend dose at each titration step
Phase
Start
Weeks
1-4
Draw Volume
0.40 mL (40 units)
Reta Delivered
2.0 mg
Cag Delivered
0.4 mg
Phase
Step 1
Weeks
5-8
Draw Volume
0.60 mL (60 units)
Reta Delivered
3.0 mg
Cag Delivered
0.6 mg
Phase
Step 2
Weeks
9-16
Draw Volume
0.80 mL (80 units)
Reta Delivered
4.0 mg
Cag Delivered
0.8 mg
Phase
Step 3
Weeks
17-20
Draw Volume
1.20 mL (120 units)
Reta Delivered
6.0 mg
Cag Delivered
1.2 mg
Phase
Step 4
Weeks
21-24
Draw Volume
1.60 mL (160 units)
Reta Delivered
8.0 mg
Cag Delivered
1.6 mg
Phase
Maintenance
Weeks
25+
Draw Volume
2.40 mL (240 units)
Reta Delivered
12.0 mg
Cag Delivered
2.4 mg
| Phase | Weeks | Draw Volume | Reta Delivered | Cag Delivered |
|---|---|---|---|---|
| Start | 1-4 | 0.40 mL (40 units) | 2.0 mg | 0.4 mg |
| Step 1 | 5-8 | 0.60 mL (60 units) | 3.0 mg | 0.6 mg |
| Step 2 | 9-16 | 0.80 mL (80 units) | 4.0 mg | 0.8 mg |
| Step 3 | 17-20 | 1.20 mL (120 units) | 6.0 mg | 1.2 mg |
| Step 4 | 21-24 | 1.60 mL (160 units) | 8.0 mg | 1.6 mg |
| Maintenance | 25+ | 2.40 mL (240 units) | 12.0 mg | 2.4 mg |
One injection per week. Hold each step at least 4 weeks. Drop back a step if GI side effects are intense.
More flexible. Lets you titrate each compound on its own schedule. Used for proper staggered co-titration.
Separate vials let you start retatrutide first, build tolerance, then layer in cagrilintide. This is the safer approach for first-time stack users because it lets you tell which compound is causing any side effect. The trade-off is two injections per week (different sites, same day or split days) and two reconstitutions.
Separate-vial workflow
Staggered Co-Titration - Two Vials, Two Schedules
Run retatrutide alone for 8 weeks, then add cagrilintide at the lowest dose. Step both compounds up slowly across the next 16 weeks.
Injection burden
2 injections per week from Week 9 on
Best for
First-time stack users; staggered titration
Cycle driver
GI tolerance sets the pace
Retatrutide
- Loading
- 2 mg → 4 mg → 8 mg (weeks 1-12)
- Frequency
- Once weekly
- Maintenance
- 12 mg weekly
- Route
- SubQ
Cagrilintide
- Loading
- Start Week 9: 0.25 → 0.5 → 1.0 → 1.7 mg
- Frequency
- Once weekly
- Maintenance
- 2.4 mg weekly
- Route
- SubQ
Weekly Schedule Example (Maintenance Phase)
Monday
Retatrutide 12 mg (one site) + Cagrilintide 2.4 mg (different site)
Tuesday
No injections
Wednesday
No injections
Thursday
No injections
Friday
No injections
Saturday
No injections
Sunday
No injections
Both compounds are once-weekly. Use separate syringes - do not mix them. Pick the same day for consistency. Rotate sites across abdomen, thigh, and flank to prevent local irritation.
Full Staggered Titration Schedule
Recommended staggered co-titration across 24 weeks
Phase
Reta initiation
Weeks
1-4
Retatrutide
2 mg/week
Cagrilintide
Not started
Notes
Confirm retatrutide GI tolerance first.
Phase
Reta escalation 1
Weeks
5-8
Retatrutide
4 mg/week
Cagrilintide
Not started
Notes
Continue retatrutide alone.
Phase
Cag introduction
Weeks
9-12
Retatrutide
4 mg/week (hold)
Cagrilintide
0.25 mg/week
Notes
Add cagrilintide at the lowest dose. Hold reta steady.
Phase
Dual escalation 1
Weeks
13-16
Retatrutide
8 mg/week
Cagrilintide
0.5 mg/week
Notes
GI effects often peak here.
Phase
Dual escalation 2
Weeks
17-20
Retatrutide
8 mg/week (hold)
Cagrilintide
1.0 mg/week
Notes
Hold reta, raise cag.
Phase
Dual escalation 3
Weeks
21-24
Retatrutide
12 mg/week
Cagrilintide
1.7 mg/week
Notes
Approach maintenance.
Phase
Maintenance
Weeks
25+
Retatrutide
12 mg/week
Cagrilintide
2.4 mg/week
Notes
Full four-receptor coverage if tolerated.
| Phase | Weeks | Retatrutide | Cagrilintide | Notes |
|---|---|---|---|---|
| Reta initiation | 1-4 | 2 mg/week | Not started | Confirm retatrutide GI tolerance first. |
| Reta escalation 1 | 5-8 | 4 mg/week | Not started | Continue retatrutide alone. |
| Cag introduction | 9-12 | 4 mg/week (hold) | 0.25 mg/week | Add cagrilintide at the lowest dose. Hold reta steady. |
| Dual escalation 1 | 13-16 | 8 mg/week | 0.5 mg/week | GI effects often peak here. |
| Dual escalation 2 | 17-20 | 8 mg/week (hold) | 1.0 mg/week | Hold reta, raise cag. |
| Dual escalation 3 | 21-24 | 12 mg/week | 1.7 mg/week | Approach maintenance. |
| Maintenance | 25+ | 12 mg/week | 2.4 mg/week | Full four-receptor coverage if tolerated. |
Step back if GI side effects become intense. Holding a step longer is always better than pushing through.
Cycle Guidelines
Common Cagrilintide + Retatrutide Cycle Approaches
Approach
Full staggered titration
Duration
24-week ramp + open-ended maintenance
Off Period
Community: 16-24 weeks on, 4-8 weeks off
Best For
Primary weight-loss strategy with full pathway coverage
Approach
Reta-first, cag add-on
Duration
Stabilize reta at 8-12 mg, then add cag for 12+ weeks
Off Period
Cag can be cycled on its own
Best For
Users already on retatrutide who want more satiety
Approach
Short-cycle test
Duration
8-12 weeks at sub-maximal doses
Off Period
4 weeks off
Best For
Initial tolerability check
| Approach | Duration | Off Period | Best For |
|---|---|---|---|
| Full staggered titration | 24-week ramp + open-ended maintenance | Community: 16-24 weeks on, 4-8 weeks off | Primary weight-loss strategy with full pathway coverage |
| Reta-first, cag add-on | Stabilize reta at 8-12 mg, then add cag for 12+ weeks | Cag can be cycled on its own | Users already on retatrutide who want more satiety |
| Short-cycle test | 8-12 weeks at sub-maximal doses | 4 weeks off | Initial tolerability check |
Taper retatrutide at the end of a cycle rather than stopping suddenly. Cagrilintide can be stopped or kept at maintenance.
Protocol Notes
- Same day, different sites. Both compounds are subcutaneous once-weekly. Inject at different sites if dosing on the same day.
- No oral options. Neither compound is orally bioavailable in these formulations.
- GI management is critical. Slow titration is the most important variable. Protein-forward meals, plenty of water, and lower-fat foods during escalation all help with tolerance.
- Do not combine with semaglutide or tirzepatide. Retatrutide already covers GLP-1 (plus GIP and glucagon). Adding another GLP-1 compound adds redundancy and side-effect burden without extra benefit.
- Watch for dysesthesia. Retatrutide escalation has been linked to tingling, numbness, or prickling sensations in clinical trials. If you notice these, note the timing relative to dose increases.
Cagrilintide + Retatrutide Supplies Needed
Plan based on the schedule above. Pre-blend users need one vial per cycle phase. Separate-vial users need two vials per cycle phase (retatrutide + cagrilintide). Round up to leave a margin for priming losses and dropped syringes.
Recommended Supply
Use discount code PEPPAL at eligible peptide supplier checkouts.
Retatrutide Supply
Cagrilintide Supply
SiPhox Health At-Home Blood Test
Injection Supplies
Disclosure: supply links may earn PDP a commission at no cost to you.
Pre-Blend Vials (15 mg: 12.5 mg reta + 2.5 mg cag)
One vial covers about 6-10 weekly doses depending on where you are in titration.
| Cycle length | Planning note |
|---|---|
8 weeks 1 vial | Covers early titration (40-80 unit draws). |
16 weeks 2 vials | Covers mid-titration draws. |
24 weeks (full titration) 3-4 vials | Larger draws at maintenance use more vial per week. |
48 weeks (titration + maintenance) 8-10 vials | Maintenance draws of 240 units use ~16% of a vial per week. |
8 weeks
1 vial
Covers early titration (40-80 unit draws).
16 weeks
2 vials
Covers mid-titration draws.
24 weeks (full titration)
3-4 vials
Larger draws at maintenance use more vial per week.
48 weeks (titration + maintenance)
8-10 vials
Maintenance draws of 240 units use ~16% of a vial per week.
Separate Retatrutide Vials (10 mg)
For separate-vial workflows. A 10 mg vial covers 2-5 weekly doses depending on step.
| Cycle length | Planning note |
|---|---|
16 weeks 2-3 x 10 mg vials | Titration from 2 mg → 8 mg weekly. |
24 weeks 3-4 x 10 mg vials | Add 8 more weekly doses at maintenance step. |
48 weeks 6-8 x 10 mg vials | Maintenance at 12 mg drives most of the total. |
16 weeks
2-3 x 10 mg vials
Titration from 2 mg → 8 mg weekly.
24 weeks
3-4 x 10 mg vials
Add 8 more weekly doses at maintenance step.
48 weeks
6-8 x 10 mg vials
Maintenance at 12 mg drives most of the total.
Separate Cagrilintide Vials (5 mg or 10 mg)
For separate-vial workflows. Cagrilintide starts at Week 9 in the staggered approach.
| Cycle length | Planning note |
|---|---|
16 weeks 1 x 5 mg vial | Only 8 weeks of cagrilintide; low doses use little. |
24 weeks 2 x 5 mg or 1 x 10 mg | Doses are still well under 2 mg/week. |
48 weeks 3-4 x 10 mg vials | Maintenance at 2.4 mg/week drives most use. |
16 weeks
1 x 5 mg vial
Only 8 weeks of cagrilintide; low doses use little.
24 weeks
2 x 5 mg or 1 x 10 mg
Doses are still well under 2 mg/week.
48 weeks
3-4 x 10 mg vials
Maintenance at 2.4 mg/week drives most use.
Insulin Syringes (U-100)
Use 1 mL syringes for the pre-blend at maintenance (240-unit draws). 0.3 mL syringes work for separate cagrilintide doses.
| Cycle length | Planning note |
|---|---|
16 weeks ~20 syringes | Pre-blend: 1/week. Separate vials: 2/week from Week 9. |
24 weeks ~35 syringes | Account for separate vials from Week 9 onward. |
48 weeks ~70 syringes | Buy in bulk; 1 syringe per injection. |
16 weeks
~20 syringes
Pre-blend: 1/week. Separate vials: 2/week from Week 9.
24 weeks
~35 syringes
Account for separate vials from Week 9 onward.
48 weeks
~70 syringes
Buy in bulk; 1 syringe per injection.
Bacteriostatic Water
Pre-blend uses 2.5 mL per 15 mg vial. Separate vials each use 1-2 mL.
| Cycle length | Planning note |
|---|---|
16 weeks 1 x 10 mL bottle | Covers 2-4 reconstitutions with margin. |
24 weeks 1-2 x 10 mL bottles | Second bottle gives margin for more reconstitutions. |
48 weeks 2-3 x 10 mL bottles | Each new vial needs fresh BAC water. |
16 weeks
1 x 10 mL bottle
Covers 2-4 reconstitutions with margin.
24 weeks
1-2 x 10 mL bottles
Second bottle gives margin for more reconstitutions.
48 weeks
2-3 x 10 mL bottles
Each new vial needs fresh BAC water.
Round up for priming losses, dropped syringes, damaged swabs, and any protocol adjustments. Both vials are stable for 28-30 days at 2-8 °C once reconstituted, so plan vial sizes around 4-week use.
Cagrilintide + Retatrutide Blood Tests & Monitoring
This stack combines amylin and incretin-style metabolic pathways. Monitoring focuses on glucose trends, kidney/liver context, lipids, heart rate, hydration, and GI symptom burden.
Blood test markers to discuss with a clinician
Marker
A1c
Why it matters
Shows longer-term glucose control before and during metabolic-pathway stacking.
Timing
Baseline
Marker
Fasting glucose
Why it matters
Gives a current glucose snapshot when appetite, intake, and medication needs change.
Timing
Follow-up
Marker
Comprehensive metabolic panel (CMP)
Why it matters
Reviews kidney function, liver enzymes, electrolytes, and glucose, which matter with GI symptoms or dehydration.
Timing
Baseline
Marker
Lipid panel
Why it matters
Tracks cardiometabolic changes during weight-loss and metabolic shifts.
Timing
Follow-up
Marker
Blood pressure and resting heart rate
Why it matters
Adds cardiovascular context during weight loss and retatrutide-related heart-rate monitoring.
Timing
Follow-up
| Marker | Why it matters | Timing |
|---|---|---|
| A1c | Shows longer-term glucose control before and during metabolic-pathway stacking. | Baseline |
| Fasting glucose | Gives a current glucose snapshot when appetite, intake, and medication needs change. | Follow-up |
| Comprehensive metabolic panel (CMP) | Reviews kidney function, liver enzymes, electrolytes, and glucose, which matter with GI symptoms or dehydration. | Baseline |
| Lipid panel | Tracks cardiometabolic changes during weight-loss and metabolic shifts. | Follow-up |
| Blood pressure and resting heart rate | Adds cardiovascular context during weight loss and retatrutide-related heart-rate monitoring. | Follow-up |
Monitoring guidance combines trial-informed cagrilintide and retatrutide pathway concerns, with no established approved-label standard for this stack.
At-home blood test option
Easy at home option to monitor core metrics during research cycles.
Partner link: PDP may earn a commission at no cost to you.
Simple timing framework
Baseline
Discuss baseline labs before starting, especially with diabetes, kidney disease, gallbladder history, pancreatitis history, liver disease, or cardiovascular concerns.
Follow-up
Repeat metabolic markers after 4-12 weeks, with closer review during dose escalation or major appetite changes.
Longer term
For longer protocols, review metabolic, kidney, liver, and cardiovascular trends every 3-6 months with a clinician.
How to interpret the labs
- Stacking appetite pathways can increase the importance of hydration, electrolyte, and nutrition review.
- Diabetes medications may need clinician review if glucose changes with reduced intake.
- Severe abdominal pain, gallbladder symptoms, persistent vomiting, and dehydration require symptom-based review.
Do not wait for routine labs
Severe abdominal pain, persistent vomiting, fainting, dehydration, chest pain, or allergic symptoms need medical review.
Cagrilintide + Retatrutide Reconstitution Guide
Reconstitution math is different for the pre-blend versus two separate vials. The numbers below mirror the Cagrilintide protocol page and the Retatrutide protocol page so they match across the site.
Choose Your Reconstitution Format
Pre-blend math is one calculation. Separate vials need two.
One reconstitution. Both compounds delivered in the same draw.
The most common pre-blend is 15 mg total: 12.5 mg retatrutide + 2.5 mg cagrilintide. Reconstituted with 2.5 mL bacteriostatic water, this gives a combined concentration of 6.0 mg/mL.
Pre-Blend Reconstitution Math (12.5/2.5 mg, 15 mg total)
Metric
Blend composition
Value
12.5 mg retatrutide + 2.5 mg cagrilintide
Metric
BAC water added
Value
2.5 mL
Metric
Concentration
Value
5.0 mg/mL retatrutide + 1.0 mg/mL cagrilintide
Metric
Ratio held constant
Value
5:1 (reta : cag)
| Metric | Value |
|---|---|
| Blend composition | 12.5 mg retatrutide + 2.5 mg cagrilintide |
| BAC water added | 2.5 mL |
| Concentration | 5.0 mg/mL retatrutide + 1.0 mg/mL cagrilintide |
| Ratio held constant | 5:1 (reta : cag) |
What Each Draw Delivers (12.5/2.5 mg Pre-Blend)
Draw Volume
0.20 mL
Units
20 units
Retatrutide
1.0 mg
Cagrilintide
0.2 mg
Draw Volume
0.40 mL
Units
40 units
Retatrutide
2.0 mg
Cagrilintide
0.4 mg
Draw Volume
0.60 mL
Units
60 units
Retatrutide
3.0 mg
Cagrilintide
0.6 mg
Draw Volume
0.80 mL
Units
80 units
Retatrutide
4.0 mg
Cagrilintide
0.8 mg
Draw Volume
1.20 mL
Units
120 units*
Retatrutide
6.0 mg
Cagrilintide
1.2 mg
Draw Volume
1.60 mL
Units
160 units*
Retatrutide
8.0 mg
Cagrilintide
1.6 mg
Draw Volume
2.40 mL
Units
240 units*
Retatrutide
12.0 mg
Cagrilintide
2.4 mg
| Draw Volume | Units | Retatrutide | Cagrilintide |
|---|---|---|---|
| 0.20 mL | 20 units | 1.0 mg | 0.2 mg |
| 0.40 mL | 40 units | 2.0 mg | 0.4 mg |
| 0.60 mL | 60 units | 3.0 mg | 0.6 mg |
| 0.80 mL | 80 units | 4.0 mg | 0.8 mg |
| 1.20 mL | 120 units* | 6.0 mg | 1.2 mg |
| 1.60 mL | 160 units* | 8.0 mg | 1.6 mg |
| 2.40 mL | 240 units* | 12.0 mg | 2.4 mg |
* Volumes above 100 units exceed a standard 1 mL insulin syringe - split into two injections or use a larger syringe.
Other Common Blend Ratios
Alternate pre-blend formats (verify supplier label)
Blend
10/2.5 mg
Total
12.5 mg
BAC Water
2.0 mL
Reta Concentration
5.0 mg/mL
Cag Concentration
1.25 mg/mL
Blend
8/2 mg (ma-3rt / cag)
Total
10 mg
BAC Water
2.0 mL
Reta Concentration
4.0 mg/mL
Cag Concentration
1.0 mg/mL
Blend
10/2 mg (fg3-r / cag)
Total
12 mg
BAC Water
2.0 mL
Reta Concentration
5.0 mg/mL
Cag Concentration
1.0 mg/mL
| Blend | Total | BAC Water | Reta Concentration | Cag Concentration |
|---|---|---|---|---|
| 10/2.5 mg | 12.5 mg | 2.0 mL | 5.0 mg/mL | 1.25 mg/mL |
| 8/2 mg (ma-3rt / cag) | 10 mg | 2.0 mL | 4.0 mg/mL | 1.0 mg/mL |
| 10/2 mg (fg3-r / cag) | 12 mg | 2.0 mL | 5.0 mg/mL | 1.0 mg/mL |
Supplier blend names like ma-3rt, fg3-r, GLP-3, and 3R are brand aliases for retatrutide. Always confirm the actual mg breakdown on the vial label before reconstituting.
Two reconstitutions. Full dose control over each compound.
Each vial is reconstituted on its own. The tables below cover the most common vial sizes. Retatrutide is dosed in mg (2-12 mg range). Cagrilintide is also dosed in mg but at much lower doses (0.25-2.4 mg range). Label each vial clearly to avoid cross-dose errors.
Retatrutide Reconstitution
Retatrutide - dose per draw at common vial sizes
Vial Size
5 mg
BAC Water
1.0 mL
Concentration
5 mg/mL
2 mg Dose
0.40 mL (40 units)
4 mg Dose
0.80 mL (80 units)
8 mg Dose
N/A
12 mg Dose
N/A
Vial Size
10 mg
BAC Water
1.0 mL
Concentration
10 mg/mL
2 mg Dose
0.20 mL (20 units)
4 mg Dose
0.40 mL (40 units)
8 mg Dose
0.80 mL (80 units)
12 mg Dose
1.20 mL (120 units*)
Vial Size
10 mg
BAC Water
2.0 mL
Concentration
5 mg/mL
2 mg Dose
0.40 mL (40 units)
4 mg Dose
0.80 mL (80 units)
8 mg Dose
1.60 mL (160 units*)
12 mg Dose
2.40 mL (240 units*)
Vial Size
20 mg
BAC Water
2.0 mL
Concentration
10 mg/mL
2 mg Dose
0.20 mL (20 units)
4 mg Dose
0.40 mL (40 units)
8 mg Dose
0.80 mL (80 units)
12 mg Dose
1.20 mL (120 units*)
| Vial Size | BAC Water | Concentration | 2 mg Dose | 4 mg Dose | 8 mg Dose | 12 mg Dose |
|---|---|---|---|---|---|---|
| 5 mg | 1.0 mL | 5 mg/mL | 0.40 mL (40 units) | 0.80 mL (80 units) | N/A | N/A |
| 10 mg | 1.0 mL | 10 mg/mL | 0.20 mL (20 units) | 0.40 mL (40 units) | 0.80 mL (80 units) | 1.20 mL (120 units*) |
| 10 mg | 2.0 mL | 5 mg/mL | 0.40 mL (40 units) | 0.80 mL (80 units) | 1.60 mL (160 units*) | 2.40 mL (240 units*) |
| 20 mg | 2.0 mL | 10 mg/mL | 0.20 mL (20 units) | 0.40 mL (40 units) | 0.80 mL (80 units) | 1.20 mL (120 units*) |
* Volumes above 100 units exceed a standard 1 mL insulin syringe.
Cagrilintide Reconstitution
Cagrilintide - dose per draw at common vial sizes
Vial Size
5 mg
BAC Water
2.0 mL
Concentration
2.5 mg/mL
0.25 mg
0.10 mL (10 units)
0.5 mg
0.20 mL (20 units)
1.0 mg
0.40 mL (40 units)
2.4 mg
0.96 mL (96 units)
Vial Size
10 mg
BAC Water
2.0 mL
Concentration
5.0 mg/mL
0.25 mg
0.05 mL (5 units)
0.5 mg
0.10 mL (10 units)
1.0 mg
0.20 mL (20 units)
2.4 mg
0.48 mL (48 units)
Vial Size
10 mg
BAC Water
1.0 mL
Concentration
10.0 mg/mL
0.25 mg
0.025 mL (2.5 units)
0.5 mg
0.05 mL (5 units)
1.0 mg
0.10 mL (10 units)
2.4 mg
0.24 mL (24 units)
| Vial Size | BAC Water | Concentration | 0.25 mg | 0.5 mg | 1.0 mg | 2.4 mg |
|---|---|---|---|---|---|---|
| 5 mg | 2.0 mL | 2.5 mg/mL | 0.10 mL (10 units) | 0.20 mL (20 units) | 0.40 mL (40 units) | 0.96 mL (96 units) |
| 10 mg | 2.0 mL | 5.0 mg/mL | 0.05 mL (5 units) | 0.10 mL (10 units) | 0.20 mL (20 units) | 0.48 mL (48 units) |
| 10 mg | 1.0 mL | 10.0 mg/mL | 0.025 mL (2.5 units) | 0.05 mL (5 units) | 0.10 mL (10 units) | 0.24 mL (24 units) |
Cagrilintide is sensitive - inject BAC water down the vial wall and swirl gently. Do not shake.
Math verification
Retatrutide 10 mg vial + 1.0 mL BAC → 10 mg/mL. 8 mg dose = 0.80 mL (80 units). 12 mg dose = 1.20 mL (120 units). Cagrilintide 5 mg vial + 2.0 mL BAC → 2.5 mg/mL. 2.4 mg dose = 0.96 mL (96 units). Pre-blend 12.5/2.5 mg + 2.5 mL BAC → 5 mg/mL reta + 1 mg/mL cag. A 0.40 mL draw delivers 2.0 mg reta + 0.4 mg cag.
Reconstituted Stability
Stability windows for both compounds
Compound
Retatrutide
Lyophilized
12+ months at -20 °C
Reconstituted (2-8 °C)
28-30 days
Notes
Standard for GLP-class peptides.
Compound
Cagrilintide
Lyophilized
12+ months at -20 °C
Reconstituted (2-8 °C)
28-30 days
Notes
Do not shake (amyloid fibril risk). Discard cloudy solution.
Compound
Pre-blend
Lyophilized
12+ months at -20 °C
Reconstituted (2-8 °C)
28-30 days
Notes
Same window for both compounds in the blend.
| Compound | Lyophilized | Reconstituted (2-8 °C) | Notes |
|---|---|---|---|
| Retatrutide | 12+ months at -20 °C | 28-30 days | Standard for GLP-class peptides. |
| Cagrilintide | 12+ months at -20 °C | 28-30 days | Do not shake (amyloid fibril risk). Discard cloudy solution. |
| Pre-blend | 12+ months at -20 °C | 28-30 days | Same window for both compounds in the blend. |
Standard 7-Step Reconstitution
- 01
Warm up briefly
Let the lyophilized vial and BAC water reach room temperature (about 10-15 minutes).
- 02
Wipe the stoppers
Swab both vial stoppers with alcohol and let them dry.
- 03
Draw BAC water
Pull the planned BAC water volume into a sterile syringe.
- 04
Direct flow against the wall
Inject the BAC water slowly down the inside of the vial. Do not aim it at the powder. This matters more for cagrilintide than for retatrutide.
- 05
Roll, do not shake
Swirl or roll gently until fully dissolved. Shaking can damage cagrilintide.
- 06
Confirm clarity
The solution should be clear and colorless. Cloudy or particulate solutions should be discarded.
- 07
Label and refrigerate
Mark the vial with compound name, concentration, and reconstitution date. Store at 2-8 °C. Use within 28-30 days.
Calculator
Running two-compound math with different vial sizes? Use the PepPal Peptide Reconstitution Calculator and enter each compound separately for exact unit conversions.
Cagrilintide + Retatrutide Side Effects & Safety
This combination has not been tested in any trial. The safety picture is built from each compound's own data plus what we know from CagriSema. The main concern is stacked GI side effects - both compounds slow digestion through different pathways, so combining them can amplify nausea, vomiting, and constipation.
Combined and Amplified Concerns
- Stacked GI effects. Both compounds independently cause nausea, vomiting, diarrhea, and constipation. The burden is highest during weeks 9-24 when both are escalating. Slow titration is the main way to manage this.
- Dysesthesia - unusual skin sensations (retatrutide-specific). Tingling, numbness, or prickling have been reported in retatrutide trials and appear to increase at higher doses. This is a retatrutide signal, not a cagrilintide one. Note the timing if you notice it.
- Injection-site reactions. More commonly tied to cagrilintide. Rotate sites consistently across abdomen, thigh, and flank.
- Gallbladder events. Rapid weight loss raises gallstone risk regardless of which compounds drive the loss.
- Quality risk from two grey-market vials. Both compounds are investigational. Two vials means two chances for contamination, label error, or sub-spec material. Verify both against a Finnrick or comparable third-party COA. See the PepPal guide to reading COAs.
- Unknown glucagon-amylin interaction. Retatrutide hits the glucagon receptor directly. Cagrilintide acts on calcitonin-related receptors with some glucagon-adjacent effects. The combined effect on blood sugar has not been studied. Test glucose response carefully early on if you have any blood sugar concerns.
Common Community-Reported Side Effects
- Nausea, vomiting, diarrhea, constipation (worst during escalation steps).
- Injection-site redness or transient irritation (more common with cagrilintide).
- Mild fatigue during early titration.
- Strong appetite suppression - usually a feature, sometimes uncomfortable.
- Dysesthesia (tingling, numbness) at higher retatrutide doses.
Contraindication Signals
Standard conservative practice excludes anyone with active gastrointestinal disease, type 1 diabetes, prior pancreatitis, medullary thyroid carcinoma history, or active cancer from any retatrutide protocol. Adding cagrilintide raises the GI tolerance bar further.
When to reassess
If GI symptoms worsen instead of improving over the first 2-3 weeks of a step, if dysesthesia appears suddenly, or if you cannot keep food down, pause and consult a qualified clinician. For broader stacking-safety context see the PepPal side-effects guide.
Cagrilintide + Retatrutide Clinical Evidence Context
Direct stack evidence
No published human or animal trial has tested cagrilintide + retatrutide together. The evidence below is per-compound, plus the CagriSema (cagrilintide + semaglutide) Phase 3 data as the closest analog.
Retatrutide
Phase 2 (Jastreboff et al., NEJM 2023) reported 24.2% weight loss at 48 weeks at 12 mg. Phase 3 TRIUMPH-4 (NCT05931367) reported 28.7% body weight loss at 12 mg, 26.4% at 9 mg, vs 2.1% placebo at 68 weeks. The TRIUMPH program has more Phase 3 readouts expected through 2026.
See the Retatrutide protocol page for the standalone reference.
Cagrilintide
Phase 2 monotherapy (Lau et al., Lancet 2021) reported about 10.8% weight loss at 26 weeks at 4.5 mg. Phase 3 CagriSema (Garvey et al., NEJM 2025; REDEFINE-1) reported 22.7% weight loss at 68 weeks when paired with semaglutide. CagriSema's NDA was filed with FDA in December 2025.
See the Cagrilintide protocol page for the standalone reference.
Combined Stack
The cagrilintide + retatrutide combination is a pathway-coverage model. In plain terms, the stack hits weight loss from four directions: reduced appetite (GLP-1), better insulin signaling (GIP), more energy burn (glucagon), and stronger fullness (amylin). It covers more biological pathways than any other current peptide stack - but the exact combination has no clinical evidence behind it. CagriSema (cag + sema) is the closest analog with trial data.
Cagrilintide + Retatrutide Storage & Handling
Storage Reference (Both Compounds)
State
Lyophilized (long-term)
Cagrilintide
-4 °F (-20 °C), 12+ months
Retatrutide
-4 °F (-20 °C), 12+ months
State
Lyophilized (short-term)
Cagrilintide
35.6-46.4 °F (2-8 °C), several months
Retatrutide
35.6-46.4 °F (2-8 °C), several months
State
Reconstituted (liquid)
Cagrilintide
35.6-46.4 °F (2-8 °C), 28-30 days
Retatrutide
35.6-46.4 °F (2-8 °C), 28-30 days
State
Color when reconstituted
Cagrilintide
Clear, colorless
Retatrutide
Clear, colorless
State
Shake?
Cagrilintide
No - amyloid fibril risk
Retatrutide
No - standard peptide handling
State
Light protection
Cagrilintide
Yes
Retatrutide
Yes
State
Oral viable
Cagrilintide
No
Retatrutide
No
| State | Cagrilintide | Retatrutide |
|---|---|---|
| Lyophilized (long-term) | -4 °F (-20 °C), 12+ months | -4 °F (-20 °C), 12+ months |
| Lyophilized (short-term) | 35.6-46.4 °F (2-8 °C), several months | 35.6-46.4 °F (2-8 °C), several months |
| Reconstituted (liquid) | 35.6-46.4 °F (2-8 °C), 28-30 days | 35.6-46.4 °F (2-8 °C), 28-30 days |
| Color when reconstituted | Clear, colorless | Clear, colorless |
| Shake? | No - amyloid fibril risk | No - standard peptide handling |
| Light protection | Yes | Yes |
| Oral viable | No | No |
Both compounds share similar refrigerator windows. Cagrilintide is the more handling-sensitive of the two - never shake, and discard cloudy solution.
Cagrilintide + Retatrutide vs CagriSema vs Retatrutide Alone
The two most common alternatives are CagriSema (which has actual trial data as a combination) and retatrutide alone (the simplest option). The table below shows how they compare.
Receptor key: AMY = amylin receptors (fullness signaling). GLP-1R = appetite suppression. GIPR = insulin sensitivity / metabolic efficiency. GCGR = glucagon receptor (energy burn and fat oxidation).
How the cagrilintide + retatrutide stack compares
Feature
Components
Cagrilintide + Retatrutide
Cagrilintide + Retatrutide
CagriSema (Cag + Sema)
Cagrilintide + Semaglutide
Retatrutide Alone
Retatrutide only
Feature
Receptor coverage
Cagrilintide + Retatrutide
AMY + GLP-1R + GIPR + GCGR
CagriSema (Cag + Sema)
AMY + GLP-1R
Retatrutide Alone
GLP-1R + GIPR + GCGR
Feature
Combination clinical data
Cagrilintide + Retatrutide
None (speculative)
CagriSema (Cag + Sema)
Phase 3 REDEFINE-1: ~22.7% at 68 weeks
Retatrutide Alone
Not a combination; Phase 3 monotherapy available
Feature
Expected GI burden
Cagrilintide + Retatrutide
Very high
CagriSema (Cag + Sema)
High
Retatrutide Alone
High
Feature
Dysesthesia risk
Cagrilintide + Retatrutide
Yes (retatrutide component)
CagriSema (Cag + Sema)
No
Retatrutide Alone
Yes
Feature
Injections per week
Cagrilintide + Retatrutide
2 (separate) or 1 (pre-blend)
CagriSema (Cag + Sema)
1 or 2
Retatrutide Alone
1
Feature
Regulatory status
Cagrilintide + Retatrutide
Neither approved; no combo data
CagriSema (Cag + Sema)
NDA under FDA review
Retatrutide Alone
Phase 3 ongoing
Feature
Estimated grey-market cost
Cagrilintide + Retatrutide
$600-$1,200/month
CagriSema (Cag + Sema)
$500-$900/month
Retatrutide Alone
$300-$600/month
| Feature | Cagrilintide + Retatrutide | CagriSema (Cag + Sema) | Retatrutide Alone |
|---|---|---|---|
| Components | Cagrilintide + Retatrutide | Cagrilintide + Semaglutide | Retatrutide only |
| Receptor coverage | AMY + GLP-1R + GIPR + GCGR | AMY + GLP-1R | GLP-1R + GIPR + GCGR |
| Combination clinical data | None (speculative) | Phase 3 REDEFINE-1: ~22.7% at 68 weeks | Not a combination; Phase 3 monotherapy available |
| Expected GI burden | Very high | High | High |
| Dysesthesia risk | Yes (retatrutide component) | No | Yes |
| Injections per week | 2 (separate) or 1 (pre-blend) | 1 or 2 | 1 |
| Regulatory status | Neither approved; no combo data | NDA under FDA review | Phase 3 ongoing |
| Estimated grey-market cost | $600-$1,200/month | $500-$900/month | $300-$600/month |
Cost ranges reflect typical research-grade pricing across COA-verified suppliers as of May 2026 - verify supplier pricing before ordering.
Decision Guidance
- Choose cagrilintide + retatrutide when you want maximum theoretical pathway coverage and you accept higher cost, complexity, and uncertainty. Best for people who have already tolerated retatrutide alone.
- Choose CagriSema when you want the strongest combination evidence. CagriSema is the only one with Phase 3 combo data and a pending FDA decision.
- Choose retatrutide alone when you want the simplest protocol with strong single-agent efficacy. Retatrutide already produced 28.7% weight loss at 68 weeks on its own.
- Looking for a different second compound? The retatrutide + MOTS-c stack trades amylin satiety for mitochondrial support, and the Advanced Recomp Stack adds a GH secretagogue for lean mass.
FAQ
Q1: What is the cagrilintide + retatrutide stack?
It is a two-compound research protocol that pairs cagrilintide (an amylin analog that signals fullness through the hindbrain) with retatrutide (a triple GLP-1 / GIP / glucagon agonist). Together they cover four receptor pathways. No clinical trial has tested the exact combination, but the closely related CagriSema (cagrilintide + semaglutide) Phase 3 trial showed that adding amylin to a GLP-1 backbone improves weight loss.
Q2: What is 'cag peptide' or 'reta/cag'?
Cag is short for cagrilintide. Reta/cag (or reta-cag) is shorthand for this two-compound stack. Supplier blend names like ma-3rt / cag, fg3-r / cag, GLP-3 / cag, 3R + cagri, and AO-3RT / cag all refer to a retatrutide + cagrilintide pre-blend. The mg breakdown on the actual vial label is what matters - the brand name is just supplier shorthand.
Q3: How much cagrilintide do you take with retatrutide?
Most community protocols start cagrilintide at 0.25 mg/week once retatrutide is established, then step up every 4 weeks to 0.5, 1.0, 1.7, and 2.4 mg/week. Retatrutide titrates separately from 2 mg up to 12 mg/week. The full staggered schedule is in the dosing section.
Q4: What is in a 12.5mg / 2.5mg reta/cag blend vial?
A standard 5:1 pre-blend contains 12.5 mg retatrutide + 2.5 mg cagrilintide = 15 mg total in one vial. Reconstituted with 2.5 mL bacteriostatic water, this gives 5.0 mg/mL retatrutide + 1.0 mg/mL cagrilintide. A 0.40 mL draw delivers 2.0 mg reta + 0.4 mg cag. The full conversion table is in the reconstitution section.
Q5: How do you reconstitute the 12.5 mg / 2.5 mg reta-cag blend?
Add 2.5 mL of bacteriostatic water to the 15 mg total pre-blend vial. Inject the BAC water slowly down the inside of the glass - never aim it at the powder. Swirl gently for 30-60 seconds. Do not shake. The resulting concentration is 5.0 mg/mL retatrutide + 1.0 mg/mL cagrilintide. Use within 28-30 days when stored at 2-8 °C. The PepPal calculator handles any custom blend ratio.
Q6: Should I use a pre-blended vial or separate vials?
Pre-blend is simpler - one injection, one reconstitution, one math step. The trade-off is the fixed 5:1 ratio: you cannot raise one compound without raising the other. Separate vials are better for staggered titration (start retatrutide alone first, then add cagrilintide at Week 9) and for users who have GI sensitivity. For most first-time stack users, separate vials are the safer pick.
Q7: Can you take cagrilintide and retatrutide together?
Yes - both compounds are dosed once weekly and the schedules line up well. Same day at different injection sites is standard. The catch is that both slow digestion, so GI side effects can stack. Run retatrutide alone for the first 8 weeks, then add cagrilintide at the lowest dose (0.25 mg). Step both compounds up slowly.
Q8: What is the starting dose for cagrilintide when stacking with retatrutide?
0.25 mg/week is the standard starting dose for cagrilintide in a staggered protocol. Hold for at least 2 weeks before stepping up. The titration ladder is 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg/week, with each step usually held 2-4 weeks. Drop back a step if GI side effects are intense.
Q9: Can I lower my retatrutide if I am stacking with cagrilintide?
Some users do exactly this. The logic: cagrilintide adds amylin satiety, so the same hunger control can sometimes be reached with a lower retatrutide dose, which may reduce dysesthesia and GI side effects. A common pattern is dropping retatrutide from 12 mg to 8 mg/week once cagrilintide is at 1.7-2.4 mg/week. There is no trial confirming this works as well as the full dose of both - it is a community pattern.
Q10: Can I use cagrilintide during a retatrutide washout cycle?
Yes. Some users keep cagrilintide running during a retatrutide off-cycle to hold satiety while retatrutide clears. The typical pattern is to taper retatrutide down, keep cagrilintide at maintenance (1.7-2.4 mg/week), then resume retatrutide after a 4-8 week washout. Cagrilintide can also be cycled on its own with periodic breaks.
Q11: What can I stack to fix a plateau on retatrutide?
Common community options include adding cagrilintide for satiety, adding MOTS-c for mitochondrial support, or adding a GH secretagogue (covered in the Advanced Recomp Stack) for lean mass. None of these has direct trial data as a plateau-rescue tool. Cagrilintide is the most evidence-anchored option because CagriSema shows that adding amylin to a GLP-1 backbone improves outcomes.
Q12: What are the side effects of the cagrilintide + retatrutide stack?
The biggest one is stacked GI side effects - nausea, vomiting, diarrhea, and constipation - because both compounds slow digestion. Retatrutide can also cause dysesthesia (tingling, numbness) at higher doses. Cagrilintide is more likely to cause injection-site reactions. Rapid weight loss raises gallstone risk. See the side effects section for the full breakdown.
Q13: How does cagrilintide + retatrutide compare to CagriSema?
CagriSema pairs cagrilintide with semaglutide (a single-receptor GLP-1 drug). It has Phase 3 REDEFINE-1 data showing about 22.7% weight loss at 68 weeks, and an NDA was filed with FDA in December 2025. Cagrilintide + retatrutide swaps semaglutide for retatrutide, which already hits three receptors (GLP-1, GIP, glucagon). The reta + cag combination covers more pathways on paper, but it has no trial data of its own.
Q14: How long should I run this stack?
Most community protocols use a 24-week staggered titration to reach maintenance, then run open-ended at maintenance with periodic re-evaluation. Retatrutide trials lasted 48-68 weeks. Some users cycle the stack 16-24 weeks on, 4-8 weeks off. No validated cycle length exists for the combination specifically.
Q15: Can I combine this stack with semaglutide or tirzepatide?
Generally no. Retatrutide already covers GLP-1, GIP, and glucagon receptors. Adding semaglutide or tirzepatide adds redundant GLP-1 (and GIP, in the case of tirzepatide) activity without new pathway coverage. The result is more side effects with no extra benefit. Most researchers switch from one to another, not combine them.
Q16: Is this medical advice?
No. Everything on this page is for educational and research-reference purposes only. Neither cagrilintide nor retatrutide is FDA-approved for the use described here as of May 2026. No clinical trial has tested this exact combination. Consult a qualified healthcare provider before pursuing any peptide protocol.
Sources & Research
- 1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine (2023)
- 2. Eli Lilly and Company Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. PRNewswire / Investor Release (2025)
- 3. Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine (2025)
- 4. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity. The Lancet (2021)
- 5. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg. The Lancet (2021)
- 6. Kruse T, Dahl K, Schaffer L, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry (2021)
- 7. Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism (2026)
- 8. Fletcher MM, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications (2025)
- 9. Dutta D, et al. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian Journal of Endocrinology and Metabolism (2024)
- 10. Patient Care Online Retatrutide Achieves Up to 28.7% Weight Loss and Marked Knee Pain Reduction in Phase 3 TRIUMPH-4 Trial. Patient Care Online (2025)
- 11. ClinicalTrials.gov A Study of Retatrutide (LY3437943) Once Weekly in Adults With Obesity and Knee Osteoarthritis (TRIUMPH-4). NCT05931367. ClinicalTrials.gov (2025)
- 12. ClinicalTrials.gov REDEFINE 1 - Cagrilintide and Semaglutide in Adults with Overweight or Obesity. NCT05567796. ClinicalTrials.gov (2025)
Related Dosing Protocols
Written by Garret Grant
Founder & Lead Researcher · B.S. Civil Engineering, UCLA
Last updated: May 2026
Human-researched and AI-assisted with full editorial review. I verify sources, protocol interpretation, and final judgments personally. See methodology.
Share this page